
    
      Patients with diagnosis of clinically significant diabetic macular edema, confirmed by
      fluorangiography and OCT, undergoing to intravitreal dexamethazone injection will be enrolled
      in the study.

      Enrollment will take place according to the inclusion/exclusion criteria set by the protocol.

      The enrolled patients will be randomized for the addition or not of the curcumin formulation
      (2 tablets/die for 6 months) to intravitreal therapy.
    
  